News
ADCT
1.100
+12.51%
0.122
This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday
Benzinga · 1d ago
ADC Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Downgrades ADC Therapeutics to Neutral
Benzinga · 1d ago
ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 1d ago
Weekly Report: what happened at ADCT last week (0601-0605)?
Weekly Report · 1d ago
Assessing ADC Therapeutics (ADCT) Valuation After Pivotal LOTIS-5 Phase 3 ZYNLONTA Trial Results
Simply Wall St · 3d ago
Investors To Watch Out For Oracle, Adobe Earnings Next Week
Seeking Alpha · 3d ago
ADC Therapeutics: 'Sell' LOTIS-5 Underwhelms And Possible Change In Strategy
Seeking Alpha · 3d ago
Why Is ADC Therapeutics Stock Falling On Friday?
Benzinga · 4d ago
Analysts Are Bullish on These Healthcare Stocks: ADC Therapeutics (ADCT), Bristol-Myers Squibb (BMY)
TipRanks · 4d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 5d ago
ADC Therapeutics price target lowered to $5 from $8 at Stephens
TipRanks · 5d ago
ADC Therapeutics Price Target Cut to $2.00/Share From $6.00 by RBC Capital
Dow Jones · 5d ago
ADC Therapeutics Cut to Sector Perform From Outperform by RBC Capital
Dow Jones · 5d ago
RBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2
Benzinga · 5d ago
Why Is ADC Therapeutics Stock Falling Thursday?
Benzinga · 5d ago
ADC Therapeutics Posts Downbeat Q1 Earnings, Joins Julong Holding And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga · 5d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 5d ago
ADC Therapeutics falls on confirmatory trial data for lymphoma therapy
Seeking Alpha · 5d ago
Why Tetra Technologies Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving Premarket
Benzinga · 5d ago
More
Webull provides a variety of real-time ADCT stock news. You can receive the latest news about Adc Therapeutics Sa through multiple platforms. This information may help you make smarter investment decisions.
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.